Inhibikase Therapeutics’ $45 Million Follow-On Public Offering

Troutman Pepper Hamilton Sanders LLP advised Inhibikase Therapeutics, Inc. on the deal.Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course…

This content is for members only.
Login to Read More Join Now
Martina Bellini

Author: Martina Bellini

This content is for members only.
Login to Read More Join Now